Biomarkers
Researchers in Dr. Graff-Radford's Memory Disorders Lab are discovering new biomarkers. These findings include a study that links plasma Ab levels to an area on chromosome10. We also reported the hereditary factors related to plasma A and the risk of developing dementia as there is a drop in the plasma A42 while A40 remains high. With Rosa Rademakers, Ph.D., we have shown that the progranulin levels are an excellent way to detect progranulin mutations. We are working alongside a consortium with Sid O'Bryant, Ph.D. to standardize plasma biomarkers. We have also published a set of proteins that can distinguish Lewy body dementia from Alzheimer's disease and controls.
Related publications
- O'Bryant S, Ferman T, Zhang F, Hall J, Pedraza O, Wszolek Z, Como T, Julovich D, Mattevada S, Johnson L, Edwards M, Hall J, Graff-Radford N. A proteomic signature for dementia with Lewy bodies. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2019;11:53.
- Finch N, Baker M, Crook R, Swanson, K, Kuntz K, Surtees R, Gisceglio G, Rovelet-Lecrux A, Boeve B, Petersen R, Dickson D, Younkin S, Deramecourt V, Crook J, Graff-Radford N, Rademakers R. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132:583.
- Ertekin-Taner N, Younkin L, Yager D, Parfitt F, Baker M, Asthana S, Hutton M, Younkin S, Graff-Radford N. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology. 2008;70:596.
- Graff-Radford N, Crook J, Lucas J, Boeve B, Knopman D, Ivnik R, Smith G, Younkin L, Petersen R, Younkin S. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. JAMA Neurology. 2007;64:354.
- Ertekin-Taner N, Graff-Radford N, Younkin L, Eckman, C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin S. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees.